Elmar

NewGAMe investor group announces candidate for GAM CEO and provides funding of up to CHF 100 million

Retrieved on: 
Tuesday, September 26, 2023
GAM (company), Elmar, Swiss Financial Market Supervisory Authority, SWX, GAM, EGM, Rock, Knowledge, Growth, Julius Baer Group, Letter, CHF, Cryptocurrency, Management

The investor group comprised of NewGAMe SA and Bruellan SA, which controls approximately 9.6% of the issued share capital of GAM Holding AG [GAM:SWX] ("GAM"), announces Elmar Zumbuehl as its proposed candidate for CEO of GAM.

Key Points: 
  • The investor group comprised of NewGAMe SA and Bruellan SA, which controls approximately 9.6% of the issued share capital of GAM Holding AG [GAM:SWX] ("GAM"), announces Elmar Zumbuehl as its proposed candidate for CEO of GAM.
  • Elmar Zumbuehl, a Swiss citizen, joined GAM in 2010 and is currently Chief Risk Officer and a member of the Group Management Board.
  • Rock Investment SAS, a member of the NewGAMe investor group, has already provided short-term financing of up to CHF 20 million to cover GAM’s immediate liquidity needs.
  • We are also thrilled that Elmar has accepted the opportunity to work with the new board as CEO of GAM.

DGAP-News: QUANTRO Therapeutics appoints Dr. Elmar Maier as Independent Board Chairman

Retrieved on: 
Friday, April 30, 2021
Branches of biology, Biology, Gene expression, DNA, Molecular biology, Evolutionary developmental biology, Transcription factor, Elmar, Small molecule

Elmar holds a degree in chemistry and obtained his Ph.D. from the University of Konstanz, Germany.

Key Points: 
  • Elmar holds a degree in chemistry and obtained his Ph.D. from the University of Konstanz, Germany.
  • Dieter Nachtigall, Chief Executive Officer of QUANTRO, said: "We are delighted to have Elmar join the QUANTRO Board.
  • Throughout his career, Elmar has shown strong leadership capabilities and an innovative spirit, making him an excellent fit for QUANTRO.
  • Elmar Maier, Chairman of the Board of QUANTRO, added: "Transcription factors are key regulators of gene expression and represent a unique class of drug targets, but direct modulation by small molecules until now has been notoriously difficult.